×
ADVERTISEMENT

JANUARY 19, 2023

Study Finds Ustekinumab and Vedolizumab Equally Persistent for Crohn’s After Anti-TNFs


Originally published by our sister publication Gastroenterology & Endoscopy News

By Monica J. Smith

CHARLOTTE, N.C.—Patients with Crohn’s disease who progress from anti–tumor necrosis factor agents to one of two relatively new biologics tend to fair equally well in terms of persistence, regardless of whether they are treated with ustekinumab or vedolizumab, according to a new study.

“As we’ve heard a lot over the last decade, anti–[tumor necrosis factor